Wells Fargo raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $20 and keeps an Equal Weight rating on the shares. The firm says updated Alkermes’ (ALKS) offer looks better to Wells, with a similar upfront but better CVR terms that it thinks are likely to pay out.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Amends Agreement with Alkermes
- Alkermes increases offer to acquire Avadel Pharmaceuticals to $22.50 per share
- Avadel Pharmaceuticals put volume heavy and directionally bearish
- Avadel Pharmaceuticals Receives Superior Proposal from Lundbeck
- Avadel board declares Lundbeck proposal superior to Alkermes offer